Objective: Panic disorder (PD) is common among asthma patients and is associated with worse asthma outcomes. This may occur because of psychophysiological factors or cognitive/affective factors. This study evaluated the impact of panic attacks (PAs) on bronchoconstriction and subjective distress in people who have asthma with and without PD. Methods: A total of 25 asthma patients (15 with PD who had a PA [PD/PA], 10 without PD who did not have a PA [no PD/no PA]) were recruited from an outpatient clinic. They underwent a panic challenge (one vital capacity inhalation of 35% carbon dioxide [CO 2 ]) and completed the Panic Symptom Scale, the Subjective Distress Visual Analogue Scale, and the Borg Scale before and after CO 2 . Forced expiratory volume in 1 second was assessed pre-and post-CO 2 ; respiratory (i.e., CO 2 production, minute ventilation, tidal volume) was continuously recorded, and physiological measures (i.e., systolic and diastolic blood pressure [SBP/DBP]) were recorded every 2 minutes. Results: Analyses adjusting for age, sex, and provocative concentration of methacholine revealed no significant differences between groups in forced expiratory volume in 1 second change after CO 2 inhalation (F(1, 23) < 0.01, p = .961). However, patients with PD/PA reported more panic (F(1, 22) = 18.10, p < .001), anxiety (F(1, 22) = 21.93, p < .001), worry (F(1, 22) = 26.31, p < .001), and dyspnea (F(1,22) = 4.68, p = .042) and exhibited higher levels of CO 2 production (F(1, 2843) = 5.89, p = .015), minute ventilation (F(1, 2844) = 4.48, p = .034), and tidal volume (F(1, 2844) = 4.62, p = .032) after the CO 2 challenge, compared with patients with no PD/no PA. Conclusions: Results, presented as hypothesis generating, suggest that asthma patients with PD/PA exhibit increased panic-like anxiety, breathlessness, and a respiratory pattern consistent with hyperventilation that was not linked to statistically significant drops in bronchoconstriction.
INTRODUCTION D
uring the last decade, studies have observed a high prevalence of anxiety disorders in asthma populations, with a point prevalence of up to 34% in adults (1) . Panic disorder (PD) has been shown to be the most prevalent anxiety disorder in individuals with asthma, with rates ranging from 6.5% to 24%, which is up to 10 times the rate observed in the general population (1) (2) (3) (4) (5) . PD is characterized by sudden, recurrent panic attacks (PAs), which are episodes of intense fear or discomfort associated with at least four cognitive (e.g., fear of losing control, fear of dying) and/or physiological (e.g., shortness of breath, dizziness, chest tightness) symptoms (6) . PD has also been associated with worse asthma outcomes, including increased physician visits, emergency visits, rescue medication use, and reduced asthma-related quality of life (7) (8) (9) . The link between PD and worse asthma outcomes is quite robust, and although the mechanisms remain poorly understood, PAs may be the pathway through which they are linked.
Several theories have been developed to explain the relationship between asthma and PD and how this comorbidity may lead to worse asthma outcomes. In general, these theories may be categorized as "psychophysiological" or "cognitive/affective." The psychophysiological theory postulates that PD leads to worse asthma outcomes through direct physiological pathways, notably via anxiety (specifically panic)-induced increases in autonomic arousal leading to increased parasympathetic drive, resulting in bronchial hyperresponsiveness and obstruction (10, 11) . For example, a study from Hibbert and colleagues (1988, (10) ) monitored transcutaneous partial pressure of carbon dioxide in patients with asthma and found that hyperventilation precedes exacerbation of asthma, which suggests that panic may trigger an asthma attack through hyperventilation and airway cooling. In contrast, the cognitive/affective theory postulates that PD leads to worse asthma outcomes because of a tendency to misattribute panic-related anxiety symptoms as asthma symptoms and/or to catastrophize symptoms of breathlessness that signal a possible "asthma" attack (12, 13) . This may result in increased rescue medication use and health care seeking in the absence of true airway obstruction (7) . For example, a study from Van Peski-Oosterbaan and colleagues (1996, (13) ) found no differences in pulmonary function in patients with asthma and with (and without) PD during induced bronchoconstriction but found that patients with PD reported higher levels of breathlessness, which could be caused by catastrophization. Asthma attacks and PAs share several overlapping symptoms, such as shortness of breath, sensations of being smothered, choking, and heightened anxiety (including fears of suffocating/dying). This symptom overlap, and possible symptom confusion (12) may also influence asthma outcomes (7, 8) .
Although previous studies have found evidence supporting both theories (2, 10, 12) , results have been inconclusive and no studies to date have directly assessed the impact of PAs on both objective airway obstruction and subjective responses in documented asthmatics with PD. One of the most reliable ways to induce a PA in a laboratory setting is through carbon dioxide (CO 2 ) inhalation, which has been shown to be both safe and noninvasive (12) . A recent systematic review of the efficacy of using CO 2 challenges to induce spontaneous PAs in patients with PD (without asthma) reported that most studies used a standardized protocol of one vital capacity inhalation of 35% of CO 2 (12) . Experimental studies have also shown that patients with PD are more sensitive to 35% CO 2 inhalation than healthy individuals and those with other psychiatric disorders (e.g., generalized anxiety disorder and depression; (14, 15) ) pointing to the specificity of this challenge. We are aware of only one study to date that used 35% CO 2 challenge to induce PAs in patients with a history of respiratory disorders (i.e., asthma and bronchitis) but who did not currently have a respiratory disorder (16) . Although this study found no association between PD and increased subjective distress after the panic challenge, it did not measure any physiological (i.e., respiratory) responses, which limits its contribution. It also had the following additional methodological weaknesses: participants with current respiratory disorders were excluded, which limits its generalizability to patients with current asthma diagnoses; and patients were included on the basis of self-reports of previous histories of respiratory disorders, which may be unreliable, nonspecific, and introduces the potential for recall bias, particularly among anxious individuals who may overreport asthma (17) .
To address these limitations and more comprehensively assess the link between PD and asthma, the present study evaluated the impact of PD and PAs on bronchoconstriction, subjective distress, and physiological responses, in patients with documented asthma. It was hypothesized that asthma patients with PD who had a PA (PD/PA) in response to one vital capacity inhalation of 35% CO 2 would be more likely to exhibit (1) worse objective airway obstruction, (2) worse subjective distress, (3) greater cardiovascular activation, and (4) higher respiratory responses, compared with asthma patients without PD who did not have a PA (no PD/no PA).
METHODS

Participants
Patients with physician-diagnosed asthma were recruited between September 2011 and December 2013 from a prospective database of adult asthma and chronic obstructive pulmonary disease patients (REgistre de données en Santé Pulmonaire [RESP], database). RESP is a multicenter, prospective database of patients with adult asthma and chronic obstructive pulmonary disease. Recruitment began in 2010 and is ongoing in two centers, Hôpital du Sacré-Coeur de Montréal and the Centre Hospitalier Universitaire de Sherbrooke, in Quebec. Patients were eligible for the study if they had an asthma diagnosis confirmed by evidence of a positive methacholine challenge test (MCT, (18) ) performed in our laboratory before the experimentation, were aged 18 to 70 years, and could speak English or French. Patients were excluded if they were current smokers, had any significant medical conditions that were more serious than asthma (e.g., chronic obstructive pulmonary disease), and displayed cognitive or language deficit that would have impaired providing informed consent. Patients in the PD/PA group had to meet Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition, Text Revision (DSM-IV-TR) criteria for a primary psychiatric diagnosis of PD (19) and had to have a positive PA response to the CO 2 challenge (see details in the measures section); patients in the control group could not meet any DSM-IV-TR criteria for any current or past axis I psychiatric disorder and could not have a PA response to the CO 2 challenge. For those in the PD/PA group, they were excluded if they met criteria for a current axis I psychiatric disorder that was more severe than PD (e.g., schizophrenia, major depression), which was determined by the Anxiety Disorders Interview Schedule for DSM-IV (ADIS-IV, other anxiety or mood disorder) and/or self-reported or chart evidence of current diagnoses or medication use (psychoses).
Given the previous criteria, a total of 94 individuals were eligible to participate in this study (see flow chart of patient inclusion in Fig. 1 ). Of those, 57 declined to participate, which resulted in a sample of 37 patients (39% participation rate). Twelve patients were excluded from the analyses on the basis of their response to the CO 2 challenge (i.e., patients with PD who did not have a PA [n = 3] and patients with no PD who did have a PA [n = 9]), yielding a final sample of 25 patients (15 PD/PA and 10 no PD/no PA). Written consent was obtained from all participants and the ethics committee of the Hôpital du Sacré-Coeur de Montréal approved this project (#2003- 10-198; 2010-95) .
Study Design and Procedure
This quasi-experimental study was part of a larger research protocol assessing bronchial responsiveness to a MCT and CO 2 panic challenge in asthma patients with and without PD, and some aspects of the design have been previously described (20) . As part of a larger study, we demonstrated that asthma patients with PD who underwent an MCT experienced higher levels of subjective distress but not greater airway responsiveness (bronchoconstriction) than patients without PD, suggesting that the observed increased morbidity in asthma patients with PD is more likely due to a catastrophization of bodily symptoms rather than more severe asthma. For both studies, eligible patients were contacted by phone by a trained clinical research assistant to undergo the ADIS-IV to assess psychiatric disorders. Those who consented presented in the laboratory and completed a screening interview, which included demographic information, as well as medical and asthma history (including the Asthma Control Questionnaire [ACQ]).
On the testing day of the panic challenge study, patients were informed that they would breathe in one vital capacity inhalation of 35% CO 2 (balanced with 65% oxygen). Patients were told what symptoms they might experience (including shortness of breath and mild dizziness), but that these symptoms, if they occurred, would be temporary (lasting only a few moments) and harmless. To minimize anticipatory anxiety, they were not explicitly told that they might experience a "panic attack," which is consistent with our previous work (21) . Furthermore, patients were told that they would inhale 35% CO 2 or compressed atmospheric air but would not know which they would receive because the gas mixture was randomly selected in a double-blind fashion (although all patients received CO 2 ).
Upon presentation to the laboratory, patients were seated in a comfortable chair and were fitted with a mask that was connected to a gas analyzer (Jaeger Oxycon Pro, Carefusion, Germany), which in turn was connected online to a computer. For the inhalation of the gas mixture, patients were asked to exhale as fully as possible, then take one vital capacity inhalation of the gas, hold it for 4 seconds, and then breathe normally. Serial spirometry assessments (Spirobank G spirometer, Medical International Research, Inc, Italy) were conducted before and for 20 minutes after the inhalation at 2-minute intervals. Each time, FEV 1 was measured twice. For the purposes of this study, only the FEV 1 measured right before and right after the inhalation was analyzed. A CO 2 -induced asthma exacerbation was defined as having a 10% or more drop in their best (i.e., highest) FEV 1 postchallenge, because this drop has been reported to be the lower limit of clinical significance (22, 23) . Respiratory responses were assessed by tidal volume (VT), respiratory rate (RR), CO 2 production (VCO 2 ), oxygen uptake (VO 2 ), and minute ventilation [VE] , which were continuously recorded by the gas analyzer (24) . Breath-by-breath recordings of respiratory variables were averaged each 5 seconds, and then overall averages per group were analyzed before and after gas inhalation. To evaluate the proximal effect of the CO 2 inhalation, only the 3-minute period postinhalation was analyzed, which represents the duration range of the PA including the administration of subjective distress questionnaires. Cardiovascular activation was assessed by heart rate (HR) as well as systolic and diastolic blood pressure (SBP/DBP; Datascope Accutorr Plus, NJ), which were recorded every 2 minutes. After the gas inhalation, there was a recovery period of 20 minutes. Dyspnea (Borg Scale), subjective distress (Subjective Distress Visual Analogue Scale [SD-VAS]), and PA assessments (Panic Symptom Scale [PSS]) were administered by a trained PhD student in clinical psychology before and after the inhalation and prior to spirometry assessment.
Measures Baseline Measures
Anxiety Disorders Interview Schedule for DSM-IV
The ADIS-IV (25) is a semistructured interview typically used to confirm the diagnosis of several psychiatric disorders described in the DSM-IV, including mood and anxiety disorders. The ADIS-IV was used to determine group psychiatric status. The ADIS-IV has demonstrated good interrater reliability (k ≥ 0.81) for PD (26, 27) .
Asthma Control Questionnaire
The ACQ (28) is a seven-item self-report questionnaire that is designed to measure asthma control levels by assessing asthma symptoms, activity limitations, and bronchodilator use in the past week. An example item is: "In general, during the past week, how limited were you in your daily activities because of your asthma?" Patients rank each item on a sevenpoint scale (0 = good control, 6 = poor control), where higher scores indicate worse control. Finally, the laboratory technician completed the question on spirometry results assessing predicted FEV 1 .
Experimental Measures
Panic Symptom Scale
The PSS (29) is a 13-item questionnaire that was administered as a structured interview by a trained PhD student in clinical psychology to assess panic symptoms. This questionnaire, derived from the PA criteria listed in the DSM-III (which has not changed in the DSM-5), allows the patient to rank each panic symptom and its intensity on a five-point Likert-like scale (0 = absent to 4 = extremely severe), and the total score indicates the number of symptoms (max = 13), as well as the intensity (max = 65) of the PA. A PA in response to the CO 2 challenge was considered present when a participant endorsed the fear item on the PSS, plus at least three other items, at the end of the CO 2 challenge (6).
Borg Scale
The Borg Scale (30) is a 12-point self-report scale designed to measure perceived breathlessness and is constructed to allow the patient to rate beyond 10, indicating maximal intensity. In the field of respiratory diseases, the Borg Scale has shown good reliability and validity in adult populations (31) .
Subjective Distress Visual Analogue Scale
The SD-VAS (32) is a widely used self-report questionnaire that measures a large variety of subjective characteristics. Patients were asked to rate their agreement to three statements on their level of anxiety, discomfort, and worry, by slashing a continuous horizontal line from 0 (not at all) to 100 FIGURE 1. Flow chart of patient screening, eligibility, and participation.
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Statistical Analyses
To assess baseline differences between groups in sociodemographic, medical, asthma, and psychological characteristics, general linear models were used, with partial η 2 used as effect sizes. A similar two-group GLM was used to evaluate our first hypothesis, the relationship between PD and PA status and bronchoconstriction. To test for significant main or interaction effects of group and time on subjective distress as well as respiratory and physiological responses, a series of two-group (PD/PA and no PD/no PA) by two-time (baseline and post-CO 2 ) repeated measures mixed-model regressions were used to evaluate our second and third hypotheses. Age, sex, and provocative concentration of methacholine (PC 20 : a measure of bronchial responsiveness and proxy for asthma severity) were included as a priori covariates in all the analyses, as per the Consolidated Standards of Reporting Trials and Psychosomatic Medicine guidelines, because of their established influences on the main outcome variables (33, 34) . F 2 was used as a measure of effect size per previous work (35) . Significance was set at .05, and data analyses were performed using SAS Version 9.4 (SAS Institute, Cary NC).
RESULTS
Sample Characteristics
A total of 25 adult asthma patients were included in the present study. The mean or M (SD) age of the sample was 45 (15) (28) . Table 1 shows the sociodemographic, clinical, asthma-related, and psychological characteristics of the participants as a function of PD and PA diagnosis. Participants in the PD/PA group had a diagnosis of asthma for a significantly longer period in comparison with those in the no PD/no PA group. There were no other significant differences between groups.
Association Between PD and PA Status and Objective Airway Obstruction Association Between PD and PA Status and Subjective Distress Table 2 shows the results of the adjusted subjective distress analyses. There was a significant difference between groups for all variables, showing that patients with PD/PA had more panic symptoms and worse anxiety, discomfort, worry, and dyspnea compared with patients with no PD/no PA, regardless of time. Adjusted analyses also revealed that across both groups, the panic challenge resulted in increased panic symptoms and worse anxiety, discomfort, worry, and dyspnea. Interaction effects were also found for several subjective distress variables, which illustrated that in response to the CO 2 challenge, patients with PD/PA reported an elevated number of panic symptoms, worse anxiety, worry, and dyspnea compared with patients with no PD/no PA (Fig. 2) .
Association Between PD and PA Status and Cardiovascular Activation Table 3 shows the results of the adjusted cardiovascular activation analyses. These indicated that there was no significant difference between groups for HR, SBP, and DBP, regardless of time. In addition, only SBP was significantly higher at CO 2 postinhalation, regardless of group. No significant interaction effects were observed. Table 4 shows the results of the adjusted respiratory responses analyses. These revealed that there were no significant main effects for group or time on respiratory responses. However, three significant interaction effects were found, where patients with PD/PA experienced higher levels of VCO 2 , VE, and VT at posttest compared with patients with no PD/no PA (Fig. 3) .
Association Between PD and PA Status and Respiratory Responses
As reported in the supplemental material, a different pattern of results was observed when patients were assessed as a function of having/not having a PA, regardless of their PD diagnosis, where only a main effect of time for VCO 2 , VE, and VT were observed but no significant interaction effect (see Supplemental Digital Content 1, http://links.lww.com/PSYMED/A359).
DISCUSSION
The present study investigated bronchoconstriction and subjective distress responses to a standard panic challenge in a wellcharacterized sample of asthma patients with PD who had a PA and those without PD who did not have a PA. Our hypotheses were partially supported: patients with PD who had a PA after one vital capacity inhalation of 35% CO 2 exhibited elevated levels of subjective distress (i.e., symptoms of panic, anxiety, worry, and dyspnea) and increased respiratory responses (i.e., VCO 2 , VE, and VT) but not worse bronchoconstriction nor cardiovascular activation (i.e., HR and SBP/DBP) compared with asthma patients without PD who did not have a PA. To our knowledge, this is the first study to objectively assess both bronchoconstriction and subjective response to a simulated PA in asthmatics with versus without PD.
Contrary to our hypotheses, our results showed no difference in absolute levels of bronchoconstriction, because both groups exhibited similar levels of FEV 1 after the challenge. Although not statistically significant, patients with PD/PA were more than twice as likely to experience clinically significant bronchoconstriction (defined as a having a ≥10% drop in their FEV 1 postchallenge) than patients with no PD/no PA. This suggests that PAs may be associated with an increased risk for clinically significant bronchoconstriction under conditions of acute stress, possibly due to a hyperreactive central (autonomic) nervous system that No PD/no PA = no panic disorder and no panic attack group; PD/PA = panic disorder and panic attack group; PSS = Panic Symptom Scale; SD-VAS = Subjective Distress Visual Analogue Scale. *Significant difference between the groups set at .05. †
Adjusted for the number of panic symptoms on the PSS. Combined LABA, n (%) 47 (7) 50 (5) 0.02 .877 0.00 β-2 short action, n (%) 80 (12) 90 (9) 0.42 .524 0.02
Any antidepressants, n (%) 47 (7) 10 (1) may increase the risk for hyperventilation (36, 37) . However, this effect did not reach statistical significance in our study, possibly because of sample size (low power), and as such is only speculative at this time. Consistent with previous reports, this study showed increased subjective and respiratory responses after a 35% CO 2 challenge for patients with PD/PA, even in the absence of any objectively measured change in airway obstruction (38) , which gives further support to the cognitive/affective theory linking PD with worse asthma outcomes (20) . Indeed, PAs are often characterized by hyperventilation, which may be viewed as a compensatory phenomenon to an overly sensitive "suffocation alarm system" in patients with PD (39) . When a patient's CO 2 partial pressure rises, the system starts firing at an abnormally low threshold, which may produce a cascade of respiratory-related symptoms. These changes could possibly be misinterpreted as life-threatening asthma symptoms and trigger catastrophic fears about physiological sensations that are routinely experienced during a PA, which lead patients with PD to overreact to normal physiological variations in breathing (40) . This, in turn, can lead to a vicious cycle where the overreaction to normal bodily sensations stimulates an increase in somatic symptoms, which confirms their original catastrophic thought (41) . Nonetheless, severe asthma attacks may provide legitimate cause for patient concern and be sufficient to produce hypersensitivity to respiratory sensations, which then serve as conditioned stimuli of anxiety-induced hyperventilation and panic (2, 42, 43) . From a neural control perspective, patients with PD having a PA may have abnormally elevated respiratory responses, as seen in the current study (i.e., VT, VE), which indicates that breathing regulation may be dysfunctional (44, 45) . However, it seems like the sensation of suffocation plays a central role in both disorders; in asthma, it could be considered a "true" alarm triggered by bodily sensations related to an abnormality of peripheral respiratory mechanisms. Conversely in PD, it has been suggested to be a "false" alarm related to a dysfunctional suffocation alarm system (39, 46) . Interestingly, the supplemental analysis comparing patients who had a PA with those who did not have a PA regardless of their PD status demonstrated that the pattern of respiratory responses no longer showed any significant interaction effect but only a main effect of time for VCO 2 , VE, and VT, reflecting this tendency of hyperventilation to rebalance the O 2 uptake and CO 2 elimination. These additional findings illustrate an adjustment to the CO 2 challenge (i.e., time effect) without observing any differentiating effects of group, which suggests that only patients with PD experience abnormally elevated respiratory responses to the CO 2 compared with participants who would have had a PA regardless of their mental state (see Supplemental Digital Content 1, http://links.lww.com/PSYMED/A359). This further supports the importance of having PA's in the context of PD rather than just PAs alone.
Our findings are consistent with other cognitive/affective theory studies demonstrating no correlation between subjective distress and objective measures of asthma (47-50) but differ from those supporting a psychophysiological pathway suggesting that anxiety and mood disorders are associated with increased asthma or cardiovascular symptoms (51) (52) (53) . Nonetheless, our findings are clinically relevant because hypocapnia induced by hyperventilation, experienced during a patient's daily life, creates cognitive and respiratory symptoms that asthma patients cannot control using asthma medication, which could adversely affect their perception of control over the management of their disease (54) . This could result in overuse of medication (i.e., short-acting bronchodilators) and increased health service use (7, 8) .
The present study has some limitations that should be considered when interpreting the results. First, patients were recruited from a single tertiary care outpatient clinic, which is made up of moderate-to-severe asthma patients, so our study would generalize to a similar population but not necessarily asthma patients treated in the community. In addition, the study sample was selective (e.g., exclusion of individuals with PD who are nonpanicking) to answer the research questions and to obtain a well-characterized sample. Second, our sample size was relatively small (n = 25) and it is possible that a larger sample size may have increased power to detect a significant difference because of observed small effect size, especially regarding our findings on bronchoconstriction (partial η 2 of 0.02 for overall drop in FEV 1 postchallenge and of 0.04 for experiencing a ≥10% drop in FEV 1 postchallenge). Given the aversive nature of the study protocol, getting asthma patients with PD to participate voluntarily to experience a simulated PA was a challenge. To address the possibility of selection bias, we performed additional analyses (see Supplemental Digital Content 1, PD = panic disorder; PA = panic attack; VCO 2 = carbon dioxide production (ml/kg/min); VO 2 = oxygen uptake (ml/kg/min); VE = minute ventilation (l/min); VT = tidal volume (l); RR = respiratory rate (breaths per minute).
*Significant difference between the groups set at .0.
FIGURE 3. Interaction effect of PD and PA status and time after 35% CO 2 challenge on VCO 2 (A), VE (B), and VT (C). no PD/no PA = no panic disorder and no panic attack group; PD/PA = panic disorder and panic attack group; VCO 2 = carbon dioxide production; VE = minute ventilation; VT = tidal volume.
http://links.lww.com/PSYMED/A359) to verify whether the pattern of results changed if we looked at the effects of having a PA (or not) regardless of PD status and we observed a similar pattern of results. This increases our confidence in the generalizability of the findings. Third, it has been suggested that the use of CO 2 to induce PAs may not be optimal because the concentrations used are higher than concentrations present during "natural" PAs (55) and because of the potential bronchodilatory effects of CO 2 (56) . However, CO 2 inhalation tends to induce PAs that are milder and end quicker (i.e., when the inhalation is finished) than natural PAs (57), suggesting that our results represent at worst, conservative estimates of the true effect of naturally occurring PAs, which remain difficult to reproduce experimentally. Furthermore, CO 2 has been repeatedly shown to reliably induce PAs in similar experimental settings (12, 21, 57, 58) . Although it is true that CO 2 may induce hypercapnia, which is associated with bronchodilation, this tends to be observed in individuals with hypercapnia that is stable for at least 10 minutes. In our study, hypercapnia was only temporary (seconds to 1 minute maximum) as individuals inhaled only one vital capacity inhalation of a gas mixture containing 35% CO 2 (balanced with O 2 ) and then breathed room air. Thus, we are confident that exposures in our study were not long enough to induce bronchodilation and significantly obscure any changes in bronchoconstriction. However, it would be interesting to replicate our findings with another panicogenic substance. Fourth, one potential limitation and an area for future research would be to use other lung function measures (e.g., airway resistance, oscillatory resistance) to assess the impact of acute stress on bronchoconstriction, which are more sensitive than spirometry (59) . We chose to measure bronchoconstriction using spirometry, because of its clinical relevance and it makes our results accessible and meaningful to clinicians (60) who treat asthma and often struggle with differentiating asthma from panic/anxiety. However, it does raise the prospect that spirometry may have underestimated the effect of PD and PAs on bronchoconstriction. Future work should aim to use more sensitive measures of lung function to address this potential limitation. Fifth, the clinical research assistant assessing panic symptoms using the PSS was not blind to the psychiatric status of patients, and this may have introduced some bias. However, the PSS was administered as a structured interview, and scoring was performed separately by computer. In addition, patients were blind to which gas they would get (CO 2 or O 2 even though they all got CO 2 ), which minimizes any potential subjective bias by the clinical research assistant. In addition, the ADIS-IV was conducted by a single student, so specific interrater reliability information is not available for this study. However, it was administered by a trained PhD-level graduate student with 3 years of experience who was supervised by an experienced psychologist. Finally, we did not assess patients' perceptions about whether or not they were experiencing a panic or asthma attack during the CO 2 challenge, which limits the understanding of the impact of the cognitive interpretation on the findings. Despite these limitations, the present study also has a number of important strengths. First, this study makes a novel contribution to the existing literature by being the first, to our knowledge, to use a standardized and reliable panic challenge (one vital capacity inhalation of 35% CO 2 ) to assess bronchoconstriction and subjective responses in a well-characterized sample of objectively diagnosed asthmatics with versus without interview-derived PD. Second, we included objective measures of pulmonary function (i.e., FEV 1 ), as well as many other objective measures of respiratory and physiological responses, to assess specific and generalized arousal during a PA. Finally, we used a validated and reliable interview to assess PD and rule out any history of psychiatric disorders (i.e., ADIS-IV), and based PA diagnoses on DSM criteria.
In conclusion, this study improves our understanding of the role of PAs on objective airway obstruction, subjective and respiratory distress, and cardiovascular activation in asthma patients with and without PD. Having a PA in reaction to CO 2 was associated with elevated subjective distress and respiratory responses, but not with bronchoconstriction or cardiovascular activation, which suggests that PAs may exacerbate asthma via predominantly cognitive/affective mechanisms, although studies with larger samples are needed to replicate and confirm these findings. In addition, it would be interesting to conduct another study that uses qualitative interviews to deepen our understanding of symptom perception. Clinical trials should be considered to assess the impact of treating PD using validated strategies such as cognitive behavior therapy on symptoms, ventilatory, and airway obstruction in response to CO 2 . This could help direct treatment resources toward this subgroup of asthma patients who may be at greater risk for asthma exacerbation and morbidity as a result of their comorbid psychiatric status.
